Veracyte (VCYT) Stock Analysis

What Veracyte does

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Key metrics

ETFs linked to VCYT

Broad-market and Healthcare sector ETFs an investor holding Veracyte is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VCYT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Veracyte?

Veracyte trades under the ticker VCYT on NASDAQ.

Which exchange is VCYT listed on?

VCYT is listed on NASDAQ.

What sector does Veracyte operate in?

Veracyte is classified in the Healthcare sector (Medical - Diagnostics & Research industry).

How can PortView help analyze VCYT in a portfolio?

PortView shows VCYT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.